Cynata Therapeutics Limited (CYP.XA)
| Previous close | 0.2750 |
| Open | 0.2700 |
| Bid | 0.2500 x N/A |
| Ask | 0.2700 x N/A |
| Day's range | 0.2700 - 0.2850 |
| 52-week range | 0.1050 - 0.3400 |
| Volume | |
| Avg. volume | 32,529 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0280 |
| Earnings date | 23 July 2024 - 28 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFurther CYP-001 GvHD Clinical Data Published in Nature Medicine
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.
PR NewswirePatient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
PR NewswireFirst Patient Treated in Phase 2 GvHD Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
